The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

Alyglo ™ (immune globulin intravenous, human-stwk) 10% liquid is now available for the treatment of primary humoral immunodeficiency (PI) in adult patients 17 years of age and older.

Researchers say the data indicate cancer cases continued to be underdiagnosed in the second year of the pandemic ...

HealthDay News — An estimated 6.7% of US adults cannot use popular automatic blood pressure devices due to arm circumference, according to a research letter published online September 5 in ...

Findings seen among patients with acute ischemic stroke treated with intravenous thrombolysis within three hours after symptom onset ...

HealthDay News — Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and ...

MM-II is a proprietary suspension of large empty liposomes composed of dipalmitoylphosphatidylcholine and dimyristoylphosphatidylcholine.

Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.

The Food and Drug Administration (FDA) has granted full approval to Filspari ® (sparsentan) to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at risk ...

Vaccination effectiveness did not differ with inverse probability of vaccination weighting or for those aged 60 to 74 years and 75 years and older ...

The product can be administered subcutaneously and intravenously, though each route of administration has a different final concentration.

HealthDay News — Girls with mental illness and neurodevelopmental conditions have lower uptake of human papillomavirus (HPV) vaccination, according to a study published in the September issue of The ...